Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.
about
Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItThe important molecular markers on chromosome 17 and their clinical impact in breast cancerAdjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumabNeratinib in HER-2-positive breast cancer: results to date and clinical usefulnessSystemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineNuclear multidrug-resistance related protein 1 contributes to multidrug-resistance of mucoepidermoid carcinoma mainly via regulating multidrug-resistance protein 1: a human mucoepidermoid carcinoma cells model and Spearman's rank correlation analysisTrastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsTreatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancerMicroRNA and HER2-overexpressing cancer.Targeted and Osteo-Oncologic Treatment in Early Breast Cancer: What Is State-of-the-Art and What Might Become so within the Next 5 Years?Treating breast cancer in the 21st century: emerging biological therapiesDose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialThe advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer.For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: a meta-analysis of published literatures.Toward individualized breast cancer therapy: translating biological concepts to the bedside.Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and TrastuzumabTargeting HER2 Positive Breast Cancer with Chemopreventive Agents.Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective.The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic reviewPatterns in target-directed breast cancer research.Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysisTargeting the human epidermal growth factor receptor 2 pathway in breast cancer.Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer.HER story: the next chapter in HER-2-directed therapy for advanced breast cancer.Recent perspectives of breast cancer prognosis and predictive factors.Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells.Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement.The war on cancer: are we winning?Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.Precision treatment for cancer: role of prognostic and predictive markers.Subcutaneous trastuzumab: drug development and current position.Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases.Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.Immunotherapy for breast cancer: past, present, and future.Lapatinib: an oral dual tyrosine kinase inhibitor for HER-2-positive breast cancer.
P2860
Q26752780-B42BEC8B-25EF-453A-9276-475043061690Q26859002-D0FD6F7D-7E36-4DF3-9ACF-55D2287393AEQ27025860-706995D1-CB10-40F6-A735-3CBFDE18F98DQ27851864-2CA13419-3870-4942-B728-A73D024912C9Q28071303-44E7471E-3093-48D3-B469-0FEAFE4E2371Q28260063-E3C7134A-E7C1-44F9-84A6-C1ABC3CBA96DQ28535696-CF301304-5C1D-4D80-BC5B-F0A10AABD3D8Q33644305-AF1DF8D4-E1EE-4F73-A69F-B2D9D6FBC549Q33651550-078309C4-61F4-49A9-90F9-FA2F215A6FC4Q33994744-94F9E9CE-4FEE-4C40-BEAF-824863D0ACA7Q34042715-A3C9CADA-5B36-43D2-872D-9A904DFA41F1Q34326536-B9E706BA-5A37-4B4B-86BC-C183B8BAF121Q34468964-CFE09A98-31E8-4148-894C-E8D71FEE3698Q34648886-FB6DEF8C-C0B2-4F2B-AB02-D4E9A7686A48Q35083252-FC68F3EC-E19B-4AD8-B80B-A3960D2DD44CQ35913199-B77A52C2-AB7D-46E5-BCC0-AF9A2447F460Q35913214-55CADF47-9F1C-4758-A6F3-C1BB33DBA3E1Q36064820-E19134FB-0CC7-42D4-BCA6-097F9C01BC38Q36114852-AE5707A9-7F58-4CB1-9A95-8475148F4062Q36293907-82BBA391-9512-4A5B-9FC3-F6196510BA85Q36294151-12B04B91-546F-4809-93EF-ADD873DDFECAQ36526547-DBD05A48-D8B7-4032-8BA1-3C8D7D04077EQ36824869-7BEE4EE9-A164-4F5E-BE0A-924B175670F3Q37205811-146826C5-2866-4515-AF90-61A0642203FBQ37273125-0DBCAE0E-253F-4188-8352-258504D5C9FEQ37301435-C8537934-76E2-49B5-83B4-61829326171BQ37407119-3DC713C7-1E43-4000-A0D1-77086002CC13Q37653981-8DFB60A9-0196-490C-874C-CC26E3AD2CA5Q38061108-BE215171-D4E2-4043-85D1-0CA57AD832D7Q38097382-EE6E095C-FFFC-4111-9824-0756C0CB4FC5Q38152742-2E36953B-19E2-4D15-8C6C-17B9297723BDQ38179024-BF7D0381-0E6D-428C-894B-CA8BAE2189A4Q38207920-2C03BCDB-DF2A-47F3-AEA1-9BBC8AA8565EQ38215394-893583F7-F867-41D2-B957-12AA929516ABQ38253815-1E567866-6B56-47AE-85F8-6EE7827A12D9Q38258014-32F419E2-7EB9-44E3-BEB5-5D3B087E80CAQ38289478-B61C888A-AFEB-4E87-B9A6-C108CA5890ACQ38728508-DA6190EA-D29B-40BA-A2F3-103480E9B1E7Q38787696-B21A2B5F-8E92-4BCF-AFB3-329CBD7A6802Q38992588-041F4662-081A-45AC-BC82-A42EDB3DACB0
P2860
Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Trastuzumab in the adjuvant tr ...... randomized controlled trials.
@ast
Trastuzumab in the adjuvant tr ...... randomized controlled trials.
@en
type
label
Trastuzumab in the adjuvant tr ...... randomized controlled trials.
@ast
Trastuzumab in the adjuvant tr ...... randomized controlled trials.
@en
prefLabel
Trastuzumab in the adjuvant tr ...... randomized controlled trials.
@ast
Trastuzumab in the adjuvant tr ...... randomized controlled trials.
@en
P2093
P2860
P1433
P1476
Trastuzumab in the adjuvant tr ...... randomized controlled trials.
@en
P2093
Jinsong Lu
Wenjin Yin
Yiwei Jiang
Zhenzhou Shen
Zhimin Shao
P2860
P304
P356
10.1371/JOURNAL.PONE.0021030
P407
P577
2011-06-09T00:00:00Z